Search
Raleigh, NC Paid Clinical Trials
A listing of 194 clinical trials in Raleigh, NC actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
145 - 156 of 194
There are currently 194 clinical trials in Raleigh, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Wake Research Associates, Wake Research Associates, LLC and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Crohn's Disease Clinical Study
Recruiting
Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.
Conditions:
Crohn's Disease
Crohn Disease
Crohns Disease
Crohn's Disease (CD)
Crohn Colitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depressive disorder Clinical Study
Recruiting
A clinical study for people that suffer with Depressive disorder
Conditions:
Depressive disorder
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Recruiting
ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/21/2025
Locations: Clinical Research Site, Raleigh, North Carolina
Conditions: Binge-Eating Disorder
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Recruiting
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/21/2025
Locations: Velocity Clinical Research, Raleigh, North Carolina
Conditions: Relapsing-Remitting Multiple Sclerosis
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Duke Women's Cancer Care Raleigh, Raleigh, North Carolina +3 locations
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
Recruiting
A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: NC Nephrology, Raleigh, North Carolina
Conditions: Kidney Disease, End-Stage, End-stage Renal Disease, Arteriovenous Fistula
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
Recruiting
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/02/2025
Locations: M3 Wake Research, Inc., Raleigh, North Carolina
Conditions: Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Organ Retractor Device Study
Recruiting
This study aims to assess the safety and efficacy of an organ retraction device. The study is low risk as it is only being used in patients already undergoing primary robotic bariatric surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2024
Locations: WakeMed Health & Hospitals, Raleigh, North Carolina
Conditions: Liver Retraction During Bariatric Surgery
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
ALL
Ages:
All
Trial Updated:
12/23/2024
Locations: Not set, Raleigh, North Carolina
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill
Recruiting
The main aim of this study is to determine the impact of digital health technology, such as Alexa Skill, used to support the initiation of home-based subcutaneous immunoglobulin (SCIG) treatment, treatment management, and overall participant experience.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Research Triangle Park, Raleigh, North Carolina
Conditions: Primary Immunodeficiency Diseases (PID)
The Impact of an Evidence-Based Parenting Service on Maternal Sensitivity and Infant Cellular Aging in a Population of Under-Resourced Families
Recruiting
The goal of this clinical trial study is to learn how stress in childhood, or Early Life Adversity (ELA), gets "under the skin" and influences long-term health. The investigators will test if the support given to parents of young children reduces childhood stress. The investigators will also test if the effects of mother's stress and Early Life Adversity can be passed down to children. Can it impact the child's long-term health? Researchers will compare the Promoting First Relationships® in Prim... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: WakeMed Health & Hospitals, Raleigh, North Carolina
Conditions: Parent Child Relationship, Child Social-Emotional Development, Telomere Length, Epigenetic Aging
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
Recruiting
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and \<18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/12/2024
Locations: M3 Wake Research, Inc, Raleigh, North Carolina
Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Recruiting
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Mindpath Care Centers, Raleigh, North Carolina
Conditions: Treatment Resistant Depression
Stroke Thrombectomy and Aneurysm Registry
Recruiting
This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of blood vessels, tearing of vein, and bleeding in the brain. This information is used to help predict outcomes that undergo an operation for treatment of the above-listed brai... Read More
Gender:
ALL
Ages:
Between 1 year and 120 years
Trial Updated:
12/05/2024
Locations: University of North Carolina, Raleigh, North Carolina
Conditions: Stroke, Thromboses, Intracranial, Aneurysm, Brain
145 - 156 of 194